“Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s695. doi:10.25251/m10xva58.